In the NAFLD condition, the proportion of BAs antagonizing the FXR activity increased, which may account for, at least in part, the reduction of FGF15/19 and FGFR4-mediated signaling [117]. Here, NR1H4 is linked to metabolic dysfunction-associated steatotic liver disease.